Tag results:


Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy

[Poxel SA] POXEL SA announced that the FDA has granted Fast Track Designation to PXL770 for the treatment of patients with adrenomyeloneuropathy, the most common form of X-linked adrenoleukodystrophy.

MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

[MediciNova, Inc.] MediciNova, Inc. announced that the FDA has completed its review of a Phase II clinical trial protocol to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease, type 2 diabetes mellitus, and hypertriglyceridemia.

In Vitro Ballooned Hepatocytes Can Be Produced by Primary Human Hepatocytes and Hepatic Stellate Cell Sheets

[Scientific Reports] Researchers engineered cell sheets to develop a new in vitro model of ballooned hepatocytes.

Role of XBP1 in Regulating the Progression of Non-alcoholic Steatohepatitis

[Journal of Hepatology] Researchers investigated the role of X-box binding protein-1 (XBP1) in the progression of non-alcoholic steatohepatitis.

Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial

[Oramed Pharmaceuticals, Inc.] Oramed Pharmaceuticals, Inc. announced it has completed enrollment of all patients in a Phase II trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH).

Inventiva Announces That Its IND Application for the Phase II Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D Has Been...

[Inventiva] Inventiva announced that the US FDA has completed its safety review of the IND application and concluded that the proof-of-concept Phase II combination trial, with its lead drug candidate lanifibranor and the SGLT2 inhibitor empagliflozin1 in patients with Type 2 Diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH), may proceed.